{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:16:38Z","timestamp":1792030598937,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymgme.2023.107652","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T01:49:20Z","timestamp":1689212960000},"page":"107652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II"],"prefix":"10.1016","volume":"140","author":[{"given":"Karen S.","family":"Yee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alexanderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Merberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudan","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.H.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107652_bb0005","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D'Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107652_bb0010","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2019"},{"issue":"Suppl. 5","key":"10.1016\/j.ymgme.2023.107652_bb0015","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymgme.2023.107652_bb0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107652_bb0025","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)","volume":"155","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2023.107652_bb0030","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","author":"Tylki-Szyma\u0144ska","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymgme.2023.107652_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2023.107652_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"issue":"Suppl 2","key":"10.1016\/j.ymgme.2023.107652_bb0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13052-018-0561-2","article-title":"Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses","volume":"44","author":"Barone","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107652_bb0050","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107652_bb0055","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2023.107652_bb0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0070","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0075","first-page":"100549","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107652_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations \u2014 neurological signs and symptoms","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107652_bb0090","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0095","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2023.107652_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107652_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2023.107652_bb0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","article-title":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","volume":"21","author":"Seo","year":"2021","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.ymgme.2023.107652_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.107652_bb0125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jimd.12342","article-title":"Can serial cerebral MRIs predict the neuronopathic phenotype of MPS II?","volume":"44","author":"Vollebregt","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0130","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2023.107652_bb0135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype\u2013phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2023.107652_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2023.107652_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12881-020-01051-9","article-title":"The mutational spectrum of Hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients","volume":"21","author":"Chkioua","year":"2020","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgme.2023.107652_bb0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2016.05.003","article-title":"Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: genetic, pathological, and structural studies on iduronate-2-sulfatase","volume":"118","author":"Kosuga","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0155","series-title":"Differential Ability Scales","author":"Elliott","year":"2007"},{"key":"10.1016\/j.ymgme.2023.107652_bb0160","series-title":"Vineland Adaptive Behavior Scales","author":"Sparrow","year":"2005"},{"key":"10.1016\/j.ymgme.2023.107652_bb0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13023-021-02118-3","article-title":"Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II","volume":"16","author":"Yee","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-023-02805-3","article-title":"Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study","author":"Muenzer","year":"2023","journal-title":"Orphanet J. Rare Dis. In press"},{"key":"10.1016\/j.ymgme.2023.107652_bb0175","article-title":"Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2\/3 randomized study","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0180","series-title":"Human Genome Variation Society","author":"HGVS","year":"2022"},{"key":"10.1016\/j.ymgme.2023.107652_bb0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1073191119872250","article-title":"Projected Retained Ability Score (PRAS): a new methodology for quantifying absolute change in norm-based psychological test scores over time","volume":"28","author":"Kronenberger","year":"2021","journal-title":"Assessment"},{"key":"10.1016\/j.ymgme.2023.107652_bb0195","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cca.2021.10.020","article-title":"Identification and structure characterization of novel IDS variants causing mucopolysaccharidosis type II: a retrospective analysis of 30 Chinese children","volume":"523","author":"Zhao","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2023.107652_bb0200","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00109-006-0057-1","article-title":"Multiple cryptic splice sites can be activated by IDS point mutations generating misspliced transcripts","volume":"84","author":"Lualdi","year":"2006","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymgme.2023.107652_bb0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2014.12.299","article-title":"Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II","volume":"114","author":"Yund","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10897-013-9665-4","article-title":"MPS II: adaptive behavior of patients and impact on the family system","volume":"23","author":"Needham","year":"2014","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2023.107652_bb0215","first-page":"32","article-title":"A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II","volume":"7","author":"Shapiro","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.107652_bb0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns6030073","article-title":"Newborn screening for mucopolysaccharidosis type II in Illinois: an update","volume":"6","author":"Burton","year":"2020","journal-title":"Int. J. Neonatal Screen"},{"key":"10.1016\/j.ymgme.2023.107652_bb0225","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpeds.2018.09.063","article-title":"Taiwan national newborn screening program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI","volume":"205","author":"Chan","year":"2019","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.107652_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.107652_bb0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/ijns6040079","article-title":"Validation and implementation of a highly sensitive and efficient newborn screening assay for mucopolysaccharidosis type II","volume":"6","author":"Bilyeu","year":"2020","journal-title":"Int. J. Neonatal Screen"},{"key":"10.1016\/j.ymgme.2023.107652_bb0240","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2023.107652_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0250","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0255","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: a case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2023.107652_bb0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","article-title":"Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure","volume":"121","author":"van der Lee","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107652_bb0265","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"van der Lee","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223002822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:13:22Z","timestamp":1735233202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223002822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1096719223002822"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107652","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107652"}}